Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D (IMAGE)

Elsevier

Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D

Caption

Effect of bulevirtide (BLV) monotherapy 2 mg/day for 48 weeks on HDV RNA levels and ALT levels in 18 patients with HDV-related cirrhosis and clinically significant portal hypertension.

Credit

Journal of Hepatology

Usage Restrictions

Please include attribution.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.